Back to today’s briefing

Story perspectives

Kennedy Defends FDA Rejection Amid Oncologists' Claims

4/23/2026

43 3 Full Breakdown

Summary

Story summary

Health Secretary Robert F. Kennedy Jr. defended FDA rejection of Replimune's drug at a Senate hearing, claiming unanimous opposition from review panels.
Oncologists countered in a Wall Street Journal op-ed that an initial panel approved the drug before Dr. Vinay Prasad intervened.
Oncologists also clarified that trial participants did not receive chemotherapy, contradicting Kennedy's assertion.

1 of 1

Story summary

Health Secretary Robert F. Kennedy Jr. defended FDA rejection of Replimune's drug at a Senate hearing, claiming unanimous opposition from review panels.
Oncologists countered in a Wall Street Journal op-ed that an initial panel approved the drug before Dr. Vinay Prasad intervened.
Oncologists also clarified that trial participants did not receive chemotherapy, contradicting Kennedy's assertion.